Latest for Day One Biopharmaceuticals

Day One Biopharmaceuticals will ask regulators to approve its pediatric brain cancer drug tovorafenib before the second half of 2023, the biotech...

Day One Biopharmaceuticals has reported promising interim data from a pivotal trial of tovorafenib in relapsed pediatric low-grade glioma, marking...

Pediatric cancer biotech Day One Pharmaceuticals is headed for Nasdaq, in a move that comes less than three months after their work on a brain...

In honor of this historic event, we want to share a few thoughts about the future of targeted oncology and where we are making investments at Canaan.

Day One Biopharmaceuticals emerged in May to develop new drugs specifically for children with cancer. Now, as it ramps up its work, the company is...

The inspiration for Day One Biopharmaceuticals emerged from an inequity in patient care highlighted by leaders in the pediatric oncology community.

Day One — named for the conversations clinicians have with parents when they first tell them their child has cancer and how they hope to treat it —...

Day One is launching to develop new cancer treatments for children, but that could be used in adult patients, too.

The startup aims to develop cancer treatments for children and adults.